15 - 81 - HYPERHIDROSIS AND ANHIDROSIS Flashcards

1
Q

describe Primary focal (essential) hyperhidrosis

A
  • Idiopathic and symmetric and can affect the palms, soles, axillae, craniofacial region, groin, other areas, or combination of body sites
  • It affects males and females equally, typically begins in childhood (palmarplantar) or during puberty (axillary), and continues to persist into adulthood, with rare reports of spontaneous improvement.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

describe Secondary hyperhidrosis

A
  • Can occur from underlying systemic illnesses, medications, or both (obtaining a detailed medical history is crucial).
  • The pattern of sweating is classically generalized, but sometimes can be** focal or regional **if caused by neurologic disease or trauma, or a primary dermatologic cause (eg, eccrine nevus)
  • often persists during sleep
  • tends to present in adulthood, especially if it is caused by an underlying acquired disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Eccrine sweat glands are innervated by sympathetic nerve fibers. What is the main neurotransmitter?

A

acetylcholine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

hyperhydrosis may predispose the patient to what disorders?

A
  • pitted keratolysis,
  • dermatophytosis, and
  • verruca vulgaris or plantaris
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

To establish a diagnosis of primary focal hyperhidrosis, what symptoms should be present?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

helpful to identify the involved area of hyperhidrosis at baseline, but it does not provide any information on severity of the disease

A

Minor starch-iodine test

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

objective measurement of the amount of sweat production

A

Gravimetric (weightbased) assessment

commonly performed in clinical research studies, but it is not practical for routine clinical use

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

clinical course and prognosis of primary focal hyperhidrosis

A
  • chronic disorder, and it does not affect life expectancy
  • have a very negative impact on the quality of life, affecting all domains of social life, sense of well-being, and mental health
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

First-line therapy for primary focal hyperhidrosis

A
  • over-the-counter (OTC) antiperspirants or aluminum chloride hexahydrate (10% to 35%).
  • Topical glycopyrrolate (0.5%–2%)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

how do you apply aluminum chloride hexahydrate

A

works best when applied to dry skin at bedtime and washed off after 6 to 8 hours.

  • Patients should be counseled carefully on the proper application to reduce the risk of irritation.
  • If moisture is present on the skin when aluminum chloride hexahydrate is applied, this can result in formation of a weak hydrochloric acid, which can cause symptoms of burning, irritation, or desquamation.
  • If irritation occurs, it can usually be minimized by decreasing application to every other night or few times per week
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Hyperhidrosis Disease Severity Scale

Intolerable; always interferes

A

4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Hyperhidrosis Disease Severity Scale

Tolerable; sometimes interferes

A

2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Hyperhidrosis Disease Severity Scale

Never noticeable; never interferes

A

1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Hyperhidrosis Disease Severity Scale

Barely tolerable; frequently interferes

A

3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

approved by the U.S. Food and Drug Administration (FDA) in 2004 for the treatment of severe primary axillary hyperhidrosis in adults 18 years and older

A

onabotulinum toxin A (onabotA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

median duration of effect of toxin injection on hyperhidrosis

A

4 to 5 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Botulinum toxin injections are also used off-label for treatment of other focal areas, such as the face or scalp, palms, soles, and inframammary and inguinal folds, with average efficacy duration of approximately how many months?

A

4 to 12 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

where do you inject toxin on the skin?

A

dermal subcutaneous junction where the eccrine glands reside

20
Q
  • non-invasive procedure that can provide long-lasting reduction in axillary sweating
  • Microwave energy is readily absorbed by water molecules and as a result can easily target tissues with high water content, such as the eccrine glands
  • Eccrine glands do not regenerate, and their destruction theoretically reduces sweating in the treated area permanently
A

Electromagnetic energy thermolysis

  • Side effects are generally minor and include edema, erythema, bruising from device vacuum suction, axillary tenderness or pain, paresthesia in the axilla or upper arm, and less commonly, blisters or burns at the treatment site, scar tissue formation, and patchy axillary alopecia (permanent).
  • This technology cannot be applied to nonaxillary body
21
Q

Electromagnetic energy thermolysis cleared by the FDA in 2011 for adults with primary axillary hyperhidrosis

22
Q

uses the passage of a direct electrical current onto the skin to control of palmar-plantar hyperhidrosis

A

tap water iontophoresis therapy

  • An anticholinergic, such as glycopyrrolate, can be crushed and mixed with the water to enhance sweat reduction.
  • Side effects are typically minor (erythema, mild pain or discomfort, and paresthesia in the treatment zone) and related to higher amperage.
23
Q

Treatment Options for Primary Focal Hyperhidrosis

24
Q

This surgical procedure carries an increased risk of creating minor to severe compensatory sweating in body segments below the treated area, as well as less common complications such as Horner syndrome, bradycardia, pneumothorax requiring chest tube drainage, pleural effusion, acute bleeding or delayed hemothorax, chylothorax, and persistent intercostal neuralgia

A

endoscopic thoracic sympathectomy (ETS)

25
Q

oral agents that are commonly used as treatment for hyperhidrosis

A

anticholinergics **(glycopyrrolate and oxybutynin) **or clonidine, a centrally acting α2-adrenergic agonist.

  • Anticholinergic agents are contraindicated in those with myasthenia gravis, paralytic ileus, and pyloric stenosis and should be used with caution in patients with closed-angle glaucoma, bladder outflow obstruction, gastroesophageal reflux disease, and cardiac insufficiency.
26
Q

localized sweating on the lips, forehead, scalp, and nose while eating hot and spicy foods as a physiologic response via trigeminovascular reflex

A

GUSTATORY SWEATING

  • may also occur after upper thoracic and cervical sympathectomy, facial herpes zoster, or chorda tympani injury and has been described in association with cluster headache and diabetes mellitus
  • Treatment with topical glycopyrrolate, aluminum chloride, or botulinum toxin injection can be effective; rarely, intracranial section of the glossopharyngeal nerve or tympanic neurectomy is needed.
27
Q

pathologic gustatory sweating is usually asymmetric and intense and can occur in the distribution of the auriculotemporal nerve after injury or surgery in the region of the parotid gland

This syndrome is known as

A

Frey syndrome

  • thought to be caused by aberrant regeneration of autonomic fibers after local trauma to the auriculotemporal nerve
  • can also be seen in infants and children, often after birth trauma with forceps delivery, but cases of familial, bilateral Frey syndrome without birth trauma have been reported
28
Q

hyperhidrosis affecting the head, neck and upper trunk can occasionally affect older postmenopausal women and less commonly, men

A

PAROXYSMAL LOCALIZED HYPERHIDROSIS

29
Q

give examples of conditions which may present with excessive sweating

A

blue rubber bleb nevus syndrome, perilesional skin of a glomus tumor, tufted angioma, eccrine angiomatous hamartoma or eccrine nevus, Grierson-Gopalan disease, pachydermoperiostosis, and pretibial myxedema

30
Q

rare skin hamartoma histologically defined as focal hyperplasia or hypertrophy of eccrine glands

A

Eccrine nevus

Clinically, it presents as hyperhidrotic isolated patch of skin with no epidermal changes and is frequently located on the forearm

31
Q

Clinically, it presents as hyperhidrotic isolated patch of skin with no epidermal changes and is frequently located on the forearm

A

Eccrine nevus

Isolated case reports have shown successful response to botulinum toxin injections and topical glycopyrrolate

32
Q

some of the infectious etiologies that could present with generalized hyperhidrosis

A

Tuberculosis, malaria, brucellosis, and subacute bacterial endocarditis

33
Q

With regard to malignancy, excessive production of what interleukin by Hodgkin lymphoma cells has been shown to result in fever and subsequent night sweating?

34
Q

Riley-Day Syndrome is caused by what mutations

A

IKAP gene, located on chromosome 9

35
Q

characterized by pronounced autonomic dysregulation with profuse sweating and salivation, diminished production of tears, red blotching of the skin, absence of fungiform papillae of the tongue, episodic orthostatic hypotension, arterial hypertension, reduced deep tendon reflexes, and behavioral abnormalities

A

Familial dysautonomia (FD), also known as Riley-Day syndrome

most intensively studied of the hereditary sensoryautonomic neuropathies (designated as hereditary sensory and autonomic neuropathy [HSAN] type III)

36
Q

Generalized anhidrosis or anhidrosis with large areas of involvement usual manifestations

A
  • heat exhaustion, inability to tolerate increased physical activity in a hot environment, or dizziness upon exposure to heat

Patients with focal or segmental anhidrosis may become aware of their disease because of compensatory hyperhidrosis in other regions

37
Q

mutation of X-linked hypohidrotic ectodermal dysplasia

most common form of the ectodermal dysplasias

A

ED-1 gene encoding for ectodysplasin

38
Q

rare autosomal recessive disorder characterized by the congenital insensitivity to noxious stimuli, anhidrosis, recurrent hyperpyrexia, mental retardation, and self-mutilating behavior

A

Congenital insensitivity to pain with anhidrosis (CIPA), also known as HSAN type IV

  • reported to occur because of lossof-function variants in neurotrophic tyrosine receptor kinase 1** (NTRK1) gene**
  • Nearly all of the associated symptoms can be attributed to the inability of NTRK1 signaling pathways to regulate the development of nociceptive, sympathetic, and central cholinergic neurons
39
Q

Fabry disease is an inherited X-linked lysosomal storage disorder caused by deficient activity of what enzyme?

  • presents during childhood in both male and female patients
  • Early manifestations include hypohidrosis, telangiectasia, angiokeratoma, acroparesthesia, and gastrointestinal symptoms
  • Later in adolescence or adulthood, manifestations can include renal, cardiac, and central nervous system dysfunction
A

α-galactosidase A

40
Q

second most common symptom of Fabry disease

A

Hypohidrosis

pathogenesis is unclear but could be the result of accumulation of glycosphingolipids in eccrine sweat glands and secondary to autonomic peripheral neuropathy

41
Q

rare cause of anhidrosis that can result from idiopathic pure sudomotor failure, sudomotor neuropathy, or eccrine sweat gland failure

A

Acquired idiopathic generalized anhidrosis (AIGA)

  • has a heterogenous clinical presentation and can include the following clinical features: acute onset, cholinergic urticaria, elevated serum immunoglobulin E levels, absence of other autonomic dysfunction, and marked response to glucocorticoids.
42
Q

Miliaria results from obstruction of what structures?

A

eccrine sweat ducts and occurs in conditions of increased heat and humidity

43
Q

In miliaria crystallina, ductal obstruction occurs at what structure?

A

stratum corneum

  • It presents as small, 1-mm, clear, fragile, vesicles that rupture easily
  • They are commonly seen on the **face and upper trunk **in infants and on the trunk in adults.
44
Q

obstruction occurs deeper **within the epidermis **and results in pruritic, 1- to 3-mm, nonfollicular, erythematous macules and papules on the upper trunk and neck

A

miliaria rubra

Sterile pustules may also develop and are termed miliaria pustulosa.

45
Q
  • When miliaria rubra becomes chronic or recurrent, occlusion of eccrine sweat ducts extends to a deeper level
  • ductal obstruction occurs at the dermal–epidermal junction and produces asymptomatic, 1- to 3-mm white papules
A

miliaria profunda

46
Q

The topical application of this medication has resulted in dramatic improvement in patients with miliaria profunda

A

anhydrous lanolin